Lyell Immunopharma Statistics
Total Valuation
LYEL has a market cap or net worth of $365.34 million. The enterprise value is $215.64 million.
| Market Cap | 365.34M |
| Enterprise Value | 215.64M |
Important Dates
The last earnings date was Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LYEL has 24.59 million shares outstanding. The number of shares has increased by 45.86% in one year.
| Current Share Class | 24.51M |
| Shares Outstanding | 24.59M |
| Shares Change (YoY) | +45.86% |
| Shares Change (QoQ) | +4.59% |
| Owned by Insiders (%) | 7.23% |
| Owned by Institutions (%) | 36.48% |
| Float | 9.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24,356.10 |
| Forward PS | 20,996.64 |
| PB Ratio | 1.90 |
| P/TBV Ratio | 1.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 14,375.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.02, with a Debt / Equity ratio of 0.23.
| Current Ratio | 4.02 |
| Quick Ratio | 3.83 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -97.79% and return on invested capital (ROIC) is -40.63%.
| Return on Equity (ROE) | -97.79% |
| Return on Assets (ROA) | -36.90% |
| Return on Invested Capital (ROIC) | -40.63% |
| Return on Capital Employed (ROCE) | -88.43% |
| Weighted Average Cost of Capital (WACC) | 3.36% |
| Revenue Per Employee | $93 |
| Profits Per Employee | -$1.58M |
| Employee Count | 161 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -10.16% in the last 52 weeks. The beta is -0.09, so LYEL's price volatility has been lower than the market average.
| Beta (5Y) | -0.09 |
| 52-Week Price Change | -10.16% |
| 50-Day Moving Average | 10.86 |
| 200-Day Moving Average | 16.60 |
| Relative Strength Index (RSI) | 74.56 |
| Average Volume (20 Days) | 235,964 |
Short Selling Information
The latest short interest is 1.40 million, so 5.69% of the outstanding shares have been sold short.
| Short Interest | 1.40M |
| Short Previous Month | 1.26M |
| Short % of Shares Out | 5.69% |
| Short % of Float | 14.25% |
| Short Ratio (days to cover) | 7.91 |
Income Statement
In the last 12 months, LYEL had revenue of $15,000 and -$255.16 million in losses. Loss per share was -$11.31.
| Revenue | 15,000 |
| Gross Profit | 15,000 |
| Operating Income | -201.25M |
| Pretax Income | -255.16M |
| Net Income | -255.16M |
| EBITDA | -192.25M |
| EBIT | -201.25M |
| Loss Per Share | -$11.31 |
Balance Sheet
The company has $177.11 million in cash and $44.29 million in debt, with a net cash position of $149.70 million or $6.09 per share.
| Cash & Cash Equivalents | 177.11M |
| Total Debt | 44.29M |
| Net Cash | 149.70M |
| Net Cash Per Share | $6.09 |
| Equity (Book Value) | 192.72M |
| Book Value Per Share | 7.84 |
| Working Capital | 139.94M |
Cash Flow
In the last 12 months, operating cash flow was -$139.25 million and capital expenditures -$715,000, giving a free cash flow of -$139.97 million.
| Operating Cash Flow | -139.25M |
| Capital Expenditures | -715,000 |
| Depreciation & Amortization | 9.01M |
| Net Borrowing | n/a |
| Free Cash Flow | -139.97M |
| FCF Per Share | -$5.69 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,341,693.33% |
| Pretax Margin | -1,701,066.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LYEL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -45.86% |
| Shareholder Yield | -45.86% |
| Earnings Yield | -76.13% |
| FCF Yield | -38.31% |
Analyst Forecast
The average price target for LYEL is $37.88, which is 154.91% higher than the current price. The consensus rating is "Buy".
| Price Target | $37.88 |
| Price Target Difference | 154.91% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 943.37% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on June 2, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jun 2, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
LYEL has an Altman Z-Score of -7.52 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.52 |
| Piotroski F-Score | 1 |